Q3 FY2026 · ended Sep 30, 2026 · Revenue $285.97M, +58.1% YoY · Filed Oct 27, 2026
Kiniksa Pharmaceuticals International, plc (KNSA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $286.0 million and net income of $47.3 million. Free cash flow was $47.4 million. As of Sep 30, 2026 it held $568.8 million in cash and investments and $7.9 million in total debt.
Revenue
$285.97M
+58.1% vs year-ago quarter
Net income
$47.34M
+156.8% vs year-ago quarter
Operating cash flow
$47.55M
+41.2% vs year-ago quarter
Free cash flow
$47.37M
+43.5% vs year-ago quarter
EPS
$0.56
+143.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
—
Net cash
$560.87M
Q3 FY2026
Operating margin
13.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KNSA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- London
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1730430
- Former names
- Kiniksa Pharmaceuticals, Ltd. (until Jun 28, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $286.0M | $243.6M | $214.3M | $202.1M | $180.9M |
| Operating income | $54.2M | $27.2M | $29.3M | $19.8M | $24.0M |
| Net income | $47.3M | $25.4M | $22.6M | $14.2M | $18.4M |
| Diluted EPS | $0.56 | $0.30 | $0.27 | $0.17 | $0.23 |
| Operating cash flow | $47.5M | $47.2M | $50.2M | $53.9M | $33.7M |
| Free cash flow | $47.4M | $46.5M | $50.0M | $53.3M | $33.0M |
| Total assets | $983.2M | $896.1M | $825.3M | $763.6M | $712.3M |
| Total liabilities | $273.1M | $242.0M | $219.6M | $196.0M | $176.9M |
| Stockholders' equity | $710.2M | $654.1M | $605.7M | $567.6M | $535.4M |
| Cash and investments | $568.8M | $525.9M | $468.1M | $414.1M | $352.1M |
| Total debt | $7.9M | $8.9M | $9.0M | $9.5M | $9.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 22, 2026 | Oct 17, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 29, 2026 |
All 776 Kiniksa Pharmaceuticals International, plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.